Emergent BioSolutions Inc (EBS)
18 Aug 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2012||Executive Chairman of the Board|
|57||2012||President, Chief Executive Officer, Director|
|59||2012||Chief Financial Officer, Executive Vice President, Administration, Treasurer|
|46||2017||Executive Vice President - Business Operations|
|61||2014||Lead Independent Director|
- BRIEF-Emergent Biosolutions Q2 earnings per share $0.11
- BRIEF-Emergent Biosolutions awarded $23 mln to develop novel multi-drug auto-injector for U.S. Department Of Defense
- BRIEF-Emergent Biosolutions Inc - announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV
- BRIEF-Emergent Biosolutions to acquire Raxibacumab from GSK
- BRIEF-Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business